TAK, US8740602052

Analysts raised target for Takeda Pharmaceutical stock to JPY 5,800

Published on 10/13/2026 at 09:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Takeda Pharmaceutical stock costs EUR 16.55 on October 13, 2026. Core revenue fell 0.5 percent in fiscal 2026's first quarter, with results due October 29.

Key points in brief

Analysts raised Takeda Pharmaceutical's target from JPY 5,600 to JPY 5,800 on September 19, 2026.
Core revenue declined 0.5 percent at constant exchange rates in the first quarter of fiscal 2026, while reported revenue rose 10.2 percent on currency effects.
Takeda Pharmaceutical stock was trading at EUR 16.55 at Lang & Schwarz on October 13, 2026 at 9:30 a.m. CEST.
Takeda is scheduled to release second-quarter fiscal 2026 results on October 29, 2026.

TAK, US8740602052, Illustration mit AI erstellt.

Takeda Pharmaceutical (ISIN US8740602052) was tied to a higher JPY 5,800 price target, up from JPY 5,600, in an analyst update dated September 19, 2026, according to Simply Wall St. The stock was trading at EUR 16.55 at Lang & Schwarz on October 13, 2026 at 9:30 a.m. CEST.

Three milestones shape the story

On July 30, 2026, Takeda's first-quarter fiscal 2026 core revenue declined 0.5 percent at constant exchange rates, while reported revenue rose 10.2 percent because of currency effects, according to Gekko.

On September 19, 2026, the analyst target increased from JPY 5,600 to JPY 5,800, with the update citing revised assumptions for revenue growth, profit margins and future valuation, according to Simply Wall St.

On October 6, 2026, the same outlet described forecasts for 2.5 percent annual revenue growth and a margin improvement from a 3.5 percent loss position to 8.1 percent by year three, according to Simply Wall St.

What does the pipeline mean for growth

The main operating question is whether late-stage medicines can offset generic competition, pricing pressure and the cost of launches. Takeda's zasocitinib program is central to that discussion: Simply Wall St reported that the U.S. Food and Drug Administration accepted the application for Priority Review, with a decision anticipated in the first quarter of 2027.

That pipeline upside sits beside a measurable earnings reset. Takeda's first-quarter operating profit was JPY 201.4 billion and consolidated net income was JPY 113.3 billion for the three months ended June 30, 2026, while the prior quarter showed an operating loss of JPY 13.6 billion and a net loss of JPY 24.3 billion.

October brings two dated catalysts

Takeda is expected to present late-stage oncology research at an ESMO session on October 23, 2026, according to Gekko. The company's investor-relations page schedules the fiscal 2026 second-quarter earnings release for October 29, 2026, with a webcast from 7:00 p.m. to 8:15 p.m. JST, according to Takeda.

The finance quote puts Takeda's market capitalization at USD 59.4 billion as of October 12, 2026. For investors, the next earnings release will test whether the first-quarter revenue increase and pipeline milestones are translating into durable operating momentum.

Stock trades at EUR 16.55

Takeda Pharmaceutical stock was trading at EUR 16.55 at Lang & Schwarz on October 13, 2026 at 9:30 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Takeda Pharmaceutical stock.